Evidence map›Paper›PMID 33072457›Full record

ReviewCureus2020

Manganese, a Likely Cause of 'Parkinson's in Cirrhosis', a Unique Clinical Entity of Acquired Hepatocerebral Degeneration.

Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Farah Ahsan, Federico Oliveri, Harshit K Goud, Ian H Rutkofsky

Abstract readReview
In one paragraph

Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zainab MehkariInternal Medicine, California Institute of Behavioral Neuroscience & Psychology, Fairfield, USA.
Lubna MohammedInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Moiz JavedInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Aldanah AlthwanayInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Farah AhsanInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Federico OliveriCardiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Harshit K GoudInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Ian H RutkofskyPsychiatry, Neuroscience, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With idiopathic Parkinson's disease being a common entity, parkinsonism in acquired hepatocerebral degeneration (AHD) in the context of Manganese (Mn) has gained importance in recent years. An insight into the pathomechanisms behind this disease has been put forth. How can Mn as a divalent metal exert its effect in leading to chronic neurodegenerative disorder? Secondary to decreased excretion in liver cirrhosis, Mn significantly alters the striatal dopaminergic system. Management of this debilitating disease also focuses on different aspects where Mn has been involved in the pathogenesis. We have put forth the details behind Mn effects in Parkinson's, which will be a guide for better understanding and management of this disease. A literature search was performed using PubMed as a sole database, and all the articles were peer-reviewed. The author tried to follow the PRISMA guidelines. Inclusion criteria were set for 10 years, with most studies with in the last seven years. All types of study designs were included relevant to the topic, clearly delineating the pathomechanisms of Mn in the disease and also its management. After extensive research, through the PubMed database, we found that Parkinson's disease is one of the neurological complications in advanced liver cirrhosis. Mn is an essential element behind its pathogenesis; it works at different cellular levels to promote neurotoxicity. From its influx to its effects on dopamine transporters (DAT), where it disrupts dopamine homeostasis also altering postsynaptic dopamine (D2) receptors, it disrupts mitochondria and the endoplasmic reticulum (ER) promotes oxidative stress and neuroinflammation. Misfolding of alpha-synuclein (α-Syn) is promoted on chronic exposure to Mn where α-Syn from being neuroprotective becomes neurotoxic. It also alters glutaminergic and gabaergic neurotransmission. In a nutshell, the diversity of its effect on nigrostriatal denervation is challenging. The importance of neuroimaging and various approaches to management is also discussed. AHD, an uncommon entity in advanced liver cirrhosis, needs more awareness so that it can be diagnosed earlier and better therapeutic options can be sought. Our study highlighted Mn mechanisms behind this clinical entity, putting forth grounds for a better understanding of this disease. Advanced research targeting Mn for managing this disease will be revolutionary.

Indexed as

acquired hepatocerebral degenerationacquired hepatolenticular degenerationdopamine in liver cirrhosisliver cirrhosismanganese and chronic liver diseasemanganese and dopaminemanganese and dopamine transporterneurological manifestation of chronic liver diseaseparkinson cirrhosisparkinsons disease

Identifiers

PMID33072457
PMCPMC7557798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.